T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy - PubMed
8 days ago
- #Nanovesicles
- #CAR-T cell therapy
- #Rheumatoid arthritis
- T-cell-targeted fusogenic nanovesicles (FuNVCAR) generate CAR-T cells in vivo for rheumatoid arthritis (RA) therapy.
- RA is a chronic autoimmune disease driven by pathogenic B cells, causing inflammation and joint damage.
- FuNVCAR delivers preformed αCD19 CAR proteins to T cells via membrane fusion, bypassing ex vivo manufacturing and viral vectors.
- FuNVCAR-generated CAR-T cells show antigen-specific cytotoxicity against CD19+ B cells in vitro and in vivo.
- In a collagen-induced arthritis (CIA) mouse model, FuNVCAR induced CAR-T cells, leading to B-cell depletion, reduced autoantibodies, and improved joint outcomes.
- FuNVCAR demonstrated favorable tolerability with no overt organ toxicity.
- This platform offers a scalable and mechanistically distinct approach for CAR-T therapy in RA and other B cell-driven autoimmune diseases.